281 related articles for article (PubMed ID: 9311977)
1. Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution.
Papageorgiou AC; Shapiro R; Acharya KR
EMBO J; 1997 Sep; 16(17):5162-77. PubMed ID: 9311977
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the interactions of human ribonuclease inhibitor with angiogenin and ribonuclease A by mutagenesis: importance of inhibitor residues inside versus outside the C-terminal "hot spot".
Shapiro R; Ruiz-Gutierrez M; Chen CZ
J Mol Biol; 2000 Sep; 302(2):497-519. PubMed ID: 10970748
[TBL] [Abstract][Full Text] [Related]
3. Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A.
Chen CZ; Shapiro R
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1761-6. PubMed ID: 9050852
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein.
Johnson RJ; McCoy JG; Bingman CA; Phillips GN; Raines RT
J Mol Biol; 2007 Apr; 368(2):434-49. PubMed ID: 17350650
[TBL] [Abstract][Full Text] [Related]
5. Superadditive and subadditive effects of "hot spot" mutations within the interfaces of placental ribonuclease inhibitor with angiogenin and ribonuclease A.
Chen CZ; Shapiro R
Biochemistry; 1999 Jul; 38(29):9273-85. PubMed ID: 10413501
[TBL] [Abstract][Full Text] [Related]
6. Refined crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth.
Leonidas DD; Shapiro R; Allen SC; Subbarao GV; Veluraja K; Acharya KR
J Mol Biol; 1999 Jan; 285(3):1209-33. PubMed ID: 9918722
[TBL] [Abstract][Full Text] [Related]
7. Molecular recognition of human eosinophil-derived neurotoxin (RNase 2) by placental ribonuclease inhibitor.
Iyer S; Holloway DE; Kumar K; Shapiro R; Acharya KR
J Mol Biol; 2005 Apr; 347(3):637-55. PubMed ID: 15755456
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of ribonuclease inhibition by ribonuclease inhibitor protein based on the crystal structure of its complex with ribonuclease A.
Kobe B; Deisenhofer J
J Mol Biol; 1996 Dec; 264(5):1028-43. PubMed ID: 9000628
[TBL] [Abstract][Full Text] [Related]
9. Unexpected binding mode for 2'-phosphoadenosine-based nucleotide inhibitors in complex with human angiogenin revealed by heteronuclear NMR spectroscopy.
Tonan K; Xu P; Jenkins JL; Russo A; Shapiro R; Ni F
Biochemistry; 2003 Sep; 42(38):11137-49. PubMed ID: 14503864
[TBL] [Abstract][Full Text] [Related]
10. Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains.
Newton DL; Xue Y; Olson KA; Fett JW; Rybak SM
Biochemistry; 1996 Jan; 35(2):545-53. PubMed ID: 8555226
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of the complex of human RNase inhibitor and human eosinophil-derived neurotoxin (RNase 2).
Teufel DP; Kao RY; Acharya KR; Shapiro R
Biochemistry; 2003 Feb; 42(6):1451-9. PubMed ID: 12578357
[TBL] [Abstract][Full Text] [Related]
12. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity.
Boix E; Wu Y; Vasandani VM; Saxena SK; Ardelt W; Ladner J; Youle RJ
J Mol Biol; 1996 Apr; 257(5):992-1007. PubMed ID: 8632481
[TBL] [Abstract][Full Text] [Related]
13. High-resolution crystal structures of ribonuclease A complexed with adenylic and uridylic nucleotide inhibitors. Implications for structure-based design of ribonucleolytic inhibitors.
Leonidas DD; Chavali GB; Oikonomakos NG; Chrysina ED; Kosmopoulou MN; Vlassi M; Frankling C; Acharya KR
Protein Sci; 2003 Nov; 12(11):2559-74. PubMed ID: 14573867
[TBL] [Abstract][Full Text] [Related]
14. Toward rational design of ribonuclease inhibitors: high-resolution crystal structure of a ribonuclease A complex with a potent 3',5'-pyrophosphate-linked dinucleotide inhibitor.
Leonidas DD; Shapiro R; Irons LI; Russo N; Acharya KR
Biochemistry; 1999 Aug; 38(32):10287-97. PubMed ID: 10441122
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of bovine angiogenin at 1.5-A resolution.
Acharya KR; Shapiro R; Riordan JF; Vallee BL
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2949-53. PubMed ID: 7708754
[TBL] [Abstract][Full Text] [Related]
16. Crystal structures of ribonuclease A complexes with 5'-diphosphoadenosine 3'-phosphate and 5'-diphosphoadenosine 2'-phosphate at 1.7 A resolution.
Leonidas DD; Shapiro R; Irons LI; Russo N; Acharya KR
Biochemistry; 1997 May; 36(18):5578-88. PubMed ID: 9154942
[TBL] [Abstract][Full Text] [Related]
17. Crystallographic studies on structural features that determine the enzymatic specificity and potency of human angiogenin: Thr44, Thr80, and residues 38-41.
Holloway DE; Chavali GB; Hares MC; Baker MD; Subbarao GV; Shapiro R; Acharya KR
Biochemistry; 2004 Feb; 43(5):1230-41. PubMed ID: 14756559
[TBL] [Abstract][Full Text] [Related]
18. Ribonuclease inhibitor regulates neovascularization by human angiogenin.
Dickson KA; Kang DK; Kwon YS; Kim JC; Leland PA; Kim BM; Chang SI; Raines RT
Biochemistry; 2009 May; 48(18):3804-6. PubMed ID: 19354288
[TBL] [Abstract][Full Text] [Related]
19. Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin.
Shapiro R; Vallee BL
Proc Natl Acad Sci U S A; 1987 Apr; 84(8):2238-41. PubMed ID: 3470787
[TBL] [Abstract][Full Text] [Related]
20. Interaction of human placental ribonuclease with placental ribonuclease inhibitor.
Shapiro R; Vallee BL
Biochemistry; 1991 Feb; 30(8):2246-55. PubMed ID: 1998683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
